NEUROLOGICAL EMERGENCIES
Current management of ischaemic stroke R S Marshall, J P Mohr Epidemiological studies have quantified the seriousness of stroke. Its incidence averages 179 per 100 000 per year worldwide with a prevalence of 500-600 per 100 000. Eight to 20% of its victims die in the first 30 days.' Early recurrence adds to the neurological deficit and lengthens hospital stay. Late recurrence affects 4%-14% per year and five year survival averages only 56% for men, 64% for women. 2 Overall, recurrence contributes to the $16 billion in health care costs and lost productivity seen annually in the USA alone. 3 Once considered untreatable, ischaemic stroke has become subject to emerging therapies and is entering a new era, one that justifies an article focusing on treatment as well as the expected issues of diagnosis and delineation of risk factors. Increases in the understanding of the pathophysiology of stroke subtypes is steadily improving the outlook for more specific therapies for stroke analogous to the changes in outlook for myocardial infarction. Frustrated hopes for older therapies have given way to renewed confidence in newer lines of approach. Evidence from animal studies and preliminary clinical trials suggests that the ischaemic process may require several hours to develop, offering the possibility of preventing irreversible infarction. Uncontrolled intracellular influx of calcium is the current major culprit, though doubtless others will be as well documented in future. Antioxidants, free radical scavengers, and more exotic agents to block the developing necrosis after arterial occlusions are not yet well enough understood to predict their future in stroke therapy. Some of the older therapies such as anticoagulation are making a comeback whilst surgery for some indications has at last proved of value.
Hyperacute therapy for ischaemic stroke Thrombolytic therapy Increasing experience with thrombolytic agents, mainly recombinant tissue plasminogen activator(rTPA), has demonstrated instances of significant and sustained neurological improvement when thrombolytic treatment is initiated within the first few hours. Better outcomes are generally associated with documented recanalisation of the artery feeding the symptomatic region. What remains uncertain is whether the timing of therapy is more important than specific dose and whether delays increase the risk of complications, negating any benefits.
A multicentre, Phase I trial evaluated the safety and efficacy of intravenous administration of rTPA in the treatment of acute ischaemic stroke. 4 Patients were -stratified and evaluated separately for those treated within 90 minutes4 and between 91 and 1805 minutes of onset of stroke. An open-label, dose escalation study design was used. Ninety four consecutive patients were treated with intravenous rTPA at one of 7 doses, over 60 or 90 minutes. Subsequent use of anticoagulation was at the discretion of the investigators. Endpoints included intracerebral parenchymal haematoma (ICH), haemorrhagic transformation without ICH, systemic haemorrhagic complication, death, major neurological improvement at 2 and 24 hours, and neurological deterioration.
Of the 74 patients treated within 90 minutes, 32% had a decreased level of consciousness, 37% had gaze deviation, and 40% had hemiparesis. Major neurological improvement at 2 hours occurred in 30%, correlating with smaller infarct size, but not with patient age, race, gender, infarct location, severity of initial deficit, or presence of oedema. Improvement at 24 hours occurred in 46%. Neurological deterioration occurred in 11% (2 with ICH) at 24 hours, and in 8% at 7-10 days. Six patients had died at 30 days and 6 more by 3 months. Asymptomatic bleeding occurred in 4% and was not dose related. Symptomatic bleeding correlated only with total dose. The three patients (4%) who developed intracerebral haemorrhage ( versions and two died. The study was terminated early because of the strong trend toward benefit in the study group, despite the small sample size.
The second study25 randomised 225 patients to receive either IV placebo or heparin within 48 hours of stroke onset, with a target PTT of 50-70 second. The study period was seven days and no long-term anticoagulation was given. Patients were excluded from the study if they had a possible cardioembolic source, if their deficit was too severe or resolved before the start of therapy, if previous deficits existed, or if stroke progression was noted within one hour of study onset. No significant differences in stroke progression or death was seen at seven days. No difference in functional level was seen at one year. There were significantly more deaths in the heparin group at one year, although most of these deaths occurred 3-12 months after the initial stroke and "appeared unrelated to treatment."
Both studies suffered from a small sample size. They established that early recurrence was not so common as to make estimation of any therapeutic effect an easy task. Because the first study focused on cardioembolic stroke and the second excluded such patients, the conflicting conclusions cannot be directly compared. A subsequent meta-analysis26 was unable to show a benefit of anticoagulation, although most trials surveyed were before CT. The findings were of sufficient interest that a multicentre trial is underway in the USA to compare a synthetic heparin with placebo in acute stroke.27 No studies have so far determined whether differences for stroke exist according to the route of administration (IV or subcutaneous) or if IV whether continuous or bolus, or the exact dose and duration of therapy. The matter is not trivial since evidence favouring similar effects for intermittent subcutaneous heparin could easily allow treatment at home. Similarly, if continuous IV-administration is needed, it could be given by subcutaneous pump, in either case sparing hospital expense in ambulatory patients. 32 Overall, patients on warfarin had a 69% reduction in stroke risk in an "intention to treat" analysis and an 83% reduction in an "on-treatment" analysis. 33 Patients with strokes in the warfarin groups were no more likely to have haemorrhagic than ischaemic strokes. The rate of major bleeding was nearly identical for the warfarin and control groups at about two per cent; minor bleeding was three times more likely in the warfarin group.
The design of the studies varied slightly. All three studies excluded highest risk cardiac patients; those with recent embolic events, recent myocardial infarction and significant congestive heart failure or cardiomyopathy were not enrolled. SPAF excluded patients with lone atrial fibrillation, randomising them to aspirin or placebo groups only because of a low stroke risk of <0 5% per year. AFASAK excluded patients with paroxysmal atrial fibrillation for the same reason. The level of anticoagulation differed slightly. AFASAK used a prothrombin time of 1-5-2-0 times control, SPAF a prothrombin time of 1 3-1-8 times control, and BATAAF a prothrombin time of 1 2-1.5 times control. For the control groups AFASAK used ASA 75 mg/day or placebo, SPAF used 325 mg/day or placebo and BATAAF allowed ASA or no treatment to be used at the discretion of the investigators.
The AFASAK study randomised 1007 patients over a two year period. The unblinded warfarin group showed an incidence of transient ischaemic attack (TIA), stroke or systemic thromboembolism of 2% per year compared with a 5-5% incidence in the ASA and placebo arms. Three of the 5 strokes in the warfarin group had strokes when they were off warfarin. Non-fatal bleeding occurred in 6% of the warfarin group (43% of these were found to have inflammatory or malignant disease) compared with 1% in the control groups. A drawback to this study was that 38% of patients in the warfarin group dropped out, mostly because of the inconvenience of frequent blood samples.
The SPAF study randomised 1330 patients and was terminated early at a mean follow up period of 1-3 years. The incidence of stroke or systemic embolism was 2-3% in the warfarin group, 3-6% in the ASA group, and 7-4% in the placebo group. In this study as well, four of six patients with ischaemic stroke in the warfarin group had strokes off therapy. Major bleeding complications were comparable in the warfarin, ASA, and placebo groups at 1-5%, 1-4% and 1-6%, respectively.
Of the 420 patients randomised in the BAATAF study, followed for an average of years, ischaemic stroke occurred in the warfarin group at a rate of 0-41% per year and in the control group at 2-98% per year for a risk reduction of 86%. The two strokes in the warfarin group occurred at prothrombin times of <1-2. Among the strokes in the control group, eight of 13 Modification of risk factors A striking decline in age-specific stroke morbidity and mortality has been noted over the last 15 years in both women and men, with mortality rates falling in industrialised countries by 4dI%-71% 5I 52 Modification of diet and smoking behaviour, a decline in rheumatic heart disease, and improved treatment of hypertension and coronary artery disease have contributed.5" Factors that influence stroke incidence include age greater than 65 and male gender.53 Blacks are twice as prone to stroke as whites and Hispanics,54 even when controlling for a higher incidence of hypertension. 3 The difference for blacks has persisted throughout the period of overall declining mortality rates. Crucial to the management of stroke is an understanding of epidemiological predictors of stroke and stroke recurrence. Modification of risk factors has been shown to produce dramatic reductions in stroke risk. 55 Among Transient ischaemic attack may be considered both a manifestation and a risk factor for stroke. As a risk factor, TIA confers an independent relative risk of 3.9.71 TIA precedes stroke in 10% to 14% of cases.
Because the rate of stroke recurrence is so high-ranging from 4% to 14% per year depending on the study-factors have been sought which independently influence stroke recurrence. In the Lehigh Valley study, the relative risk for recurrence was in the surgical and 13 1% in the medical group. The risk of all strokes was 1 2 6% versus 27-6%, and the risk of death or major stroke was 8% versus 18&1% for the surgical and medical group respectively. Average perioperative morbidity and mortality for all centres involved was 5-8%. Perioperative incidence of major stroke or death was 2 1%. The 30-69% stenosis group is still under investigation.
Another multicentre trial, the Veterans Administration study,78 randomised 189 patients with greater than 50% internal carotid artery (ICA) stenosis to surgical plus medical therapy (ASA 325 mg) versus medical therapy alone and found similar results. At a mean follow up of 11 9 months, crescendo TIAs and stroke were found in 7-7% of patients in the surgical group versus 19-4% in the medical group for a risk reduction of 11-7%. Patients with greater than 70% stenosis showed a risk reduction of 17-7%. Perioperative morbidity and mortality in this study was 5-5%.
The largest, longest running trial is the European Carotid Surgery Trial (ECST)79
which also found a striking benefit of surgical intervention for high grade carotid stenosis among the 2518 patients they recruited. Their comparison groups were surgery plus aspirin versus aspirin alone. The high-grade stenosis (>70%) portion was terminated for this trial as well after a 9-3% risk reduction was noted for stroke or death in less than 30 days and a 9-6% reduction in stroke or death at three years.
Recruitment continues in this study also for patients with 30-69% stenosis. with Xenon CT, SPECT, and rCBF techniques are also being used to evaluate regional hypoperfusion.
In perhaps 15% of all stroke, large vessel atherosclerosis with less than haemodynamic stenosis (<80% occluded or with an ulcerated plaque) occurs in the absence of a cardioembolic source and the cause is attributed to an artery to artery embolus. Embolic fragments may arise from atherosclerotic lesions in the ICA, 00-102 the basilar artery,103 intracranial large vessels,'04 105 the proximal stump of an occluded carotid,'06 or the distal tail of a thrombus in an occluded ICA. Distinguishing inter-arterial embolism from possible cardioembolic aetiology may be difficult, however, the former usually produces a smaller cortical infarct and the latter is more often associated with a decreased level of consciousness and an abnormal initial CT. 93 Small deep lesions in the subcortical white matter, the thalamus, the basal ganglia or 
